CellaVision AB (publ)
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology la… Read more
CellaVision AB (publ) (CLVSF) - Total Liabilities
Latest total liabilities as of December 2025: $207.31 Million USD
Based on the latest financial reports, CellaVision AB (publ) (CLVSF) has total liabilities worth $207.31 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CellaVision AB (publ) - Total Liabilities Trend (2007–2025)
This chart illustrates how CellaVision AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CellaVision AB (publ) Competitors by Total Liabilities
The table below lists competitors of CellaVision AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kangxin New Materials Co Ltd
SHG:600076
|
China | CN¥2.86 Billion |
|
MEC Company Ltd.
PINK:MECGF
|
USA | $5.48 Billion |
|
Dingli Communications Corp Ltd
SHE:300050
|
China | CN¥193.36 Million |
|
Enjoyor
SHE:300020
|
China | CN¥2.42 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥4.51 Billion |
|
Fine Organic Industries Limited
NSE:FINEORG
|
India | ₹1.83 Billion |
|
Myriad Genetics Inc
NASDAQ:MYGN
|
USA | $338.60 Million |
|
Jiangsu Hanvo Safety Product Co. Ltd.
SHE:300952
|
China | CN¥1.10 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down CellaVision AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CellaVision AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CellaVision AB (publ) (2007–2025)
The table below shows the annual total liabilities of CellaVision AB (publ) from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $207.31 Million | +5.68% |
| 2024-12-31 | $196.16 Million | -7.61% |
| 2023-12-31 | $212.32 Million | -15.11% |
| 2022-12-31 | $250.12 Million | -11.28% |
| 2021-12-31 | $281.93 Million | +18.26% |
| 2020-12-31 | $238.41 Million | -18.73% |
| 2019-12-31 | $293.34 Million | +255.96% |
| 2018-12-31 | $82.41 Million | +37.93% |
| 2017-12-31 | $59.75 Million | +18.85% |
| 2016-12-31 | $50.27 Million | +36.20% |
| 2015-12-31 | $36.91 Million | -27.56% |
| 2014-12-31 | $50.95 Million | -9.11% |
| 2013-12-31 | $56.06 Million | +4.50% |
| 2012-12-31 | $53.64 Million | +1.87% |
| 2011-12-31 | $52.66 Million | +7.30% |
| 2010-12-31 | $49.08 Million | +27.30% |
| 2009-12-31 | $38.55 Million | -23.64% |
| 2008-12-31 | $50.49 Million | +109.95% |
| 2007-12-31 | $24.05 Million | -- |